Search the Newsreel

IMVT Maintained by JP Morgan -- Price Target Raised to $50.00

JP Morgan has maintained an Overweight rating on Immunovant (IMVT), increasing its price target to $50.00 from $47.00. Despite this positive analyst outlook, Immunovant holds a low GF Score™ of 29/100, indicating challenges in profitability and growth, and has seen significant insider selling. The …

IBRX Founder Soon-Shiong Bets On Anktiva's Next Growth Phase — ImmunityBio Posts Record Q2 Sales

ImmunityBio (IBRX) reported record second-quarter revenue of $51.2 million, surpassing Wall Street estimates, largely driven by strong sales of its cancer therapy, Anktiva. Despite a wider net loss due to non-cash accounting charges, Chairman Patrick Soon-Shiong highlighted the company's focus on expanding Anktiva's applications …

ImmunityBio Releases Q2 2026 Financial Results

ImmunityBio, Inc. (IBRX) reported a net loss of $230.4M and a loss per share of $0.22 for Q2 2026, widening from Q2 2025 as the company invests in its immunotherapy platform. Despite increased losses, revenue grew significantly to $51.2M, up 92.0% year-over-year, driven by …

ImmunityBio, Inc. (IBRX) Q2 2026 Earnings

ImmunityBio, Inc. (IBRX) reported its Q2 2026 earnings, with an EPS of -$0.22 against an estimated -$0.08, and revenue of $51M, exceeding the $50M estimate. The company's ANKTIVA revenue saw a 94% year-over-year increase, marking its eighth consecutive quarter of sequential gains. The EPS …

Earnings Flash (IBRX) ImmunityBio, Inc. Reports Q2 Revenue $51.2M, vs. FactSet Est of $49.7M

ImmunityBio, Inc. (IBRX) reported Q2 revenue of $51.2 million, surpassing the FactSet estimate of $49.7 million. This earnings flash indicates stronger-than-expected revenue performance for the biotechnology company in the second quarter.

ImmunityBio Q2 revenue rises 92% to record $50.7 million

ImmunityBio (IBRX) reported a significant increase in Q2 2026 total revenue, reaching $51.2 million, with net product revenue up 92% year-over-year to a record $50.7 million. The company's ANKTIVA product continues to drive growth, marking its eighth consecutive quarter of sequential revenue increase, and …

Record Q2 revenue and higher net loss at ImmunityBio (NASDAQ: IBRX)

ImmunityBio (NASDAQ: IBRX) reported record Q2 2026 net product revenue of $50.7 million, a 92% year-over-year increase, and $94.8 million for the first half of 2026. Despite this revenue growth, the company experienced a higher GAAP net loss of $230.4 million in Q2 and …

Scinai Immunotherapeutics (SCNI) Slips 6.6% as Shares Test Key Support at $0.25 - Low Volume Node

Altimmune (ALT) Projected to Release Quarterly Earnings on Tuesday

FDA Sets Jan. 6 Target Date for ImmunityBio's ANKTIVA Review

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Average Rating of "Hold" by Brokerages

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) has received a consensus "Hold" rating from ten research firms, with an average 12-month price target of $56.71. Despite beating EPS expectations with $0.25 against a consensus loss of $0.26, the company's revenue of $106.68 million fell short …

Altimmune (ALT) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $ALT

This article provides a comprehensive overview of Altimmune's FDA-related activities for its drug pemvidutide, detailing clinical trial updates, regulatory submissions, and designations through 2026. Pemvidutide is being developed for conditions including obesity, MASH (metabolic dysfunction-associated steatohepatitis),

Altimmune (ALT) CFO acquires 1,753 shares via employee stock purchase plan

Altimmune, Inc. (ALT) CFO Gregory L. Weaver acquired 1,753 shares of common stock on July 31, 2026, through the company's 2019 Employee Stock Purchase Plan (ESPP). The shares were purchased at $2.414 each, representing 85% of the closing price on that day, for the …

Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IBRX) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ImmunityBio, Inc. (NASDAQ:IBRX) securities who bought shares prior to January 19, 2026, and continue to hold them. The investigation aims to determine if ImmunityBio and its officers engaged in corporate …

Estrella Immunopharma Activates Oregon Health & Science University as Third Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma

Estrella Immunopharma has announced the activation of Oregon Health & Science University as the third clinical site for its STARLIGHT-1 Phase I/II trial. This trial is evaluating EB103, a CD19-Redirected ARTEMIS® T-cell therapy, for patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. The company …

Estrella adds third site to EB103 lymphoma trial

Estrella Immunopharma Inc. has activated Oregon Health & Science University as the third clinical site for its STARLIGHT-1 Phase I/II trial of EB103. The trial evaluates EB103, a CD19-Redirected ARTEMIS T-cell therapy, in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. This expansion will …

Altimmune Initiates PERFORMA Phase 3 Trial Of Pemvidutide In Patients With Mash

Altimmune has announced the initiation of its PERFORMA Phase 3 trial for pemvidutide. This trial focuses on evaluating the drug's efficacy in patients diagnosed with MASH (Metabolic Dysfunction-Associated Steatohepatitis). The information was released via Reuters and is available on TradingView.

IMUX Q1 2026 Earnings: Wider-than-Expected Net Loss of $1.08 per Share Underscores Pre-Revenue Pipeline Investment - Tangible Book Value

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 4.9% - Should You Sell?

OMERS ADMINISTRATION Corp Makes New Investment in Immunic, Inc. $IMUX

OMERS ADMINISTRATION Corp recently invested in Immunic, Inc. (NASDAQ:IMUX) by acquiring 168,300 shares valued at approximately $187,000, representing about 1.24% of the company. Despite a recent earnings miss, analysts maintain a "Buy" consensus rating with an average price target of $47.57. Immunic, a biopharmaceutical …

ETFs Investing in Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh Stocks

This article lists various ETFs that include Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh stocks in their portfolios. The funds are sorted by market value and provide key financial metrics such as weight, issuer, management style, expense ratio, AUM, price, …

ACIU Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift Shares - Analyst Drop Coverage

Immunovant (IMVT) Stock Forum and Discussion

This page provides a stock forum and discussion platform for Immunovant (IMVT). It allows investors and interested parties to share insights, opinions, and analysis related to the company's stock performance and future prospects. The forum serves as a community hub for active engagement on …

Immutep (NASDAQ: IMMP) ends lung trial, extends cash runway

Immutep Limited (NASDAQ: IMMP) reported mixed Q4 FY26 results, discontinuing its Phase III TACTI-004 lung cancer trial due to futility but showing positive progress in other programs like INSIGHT-003 and IMP761. The company maintains strong liquidity with A$68.87 million in cash and cash equivalents, …

ImmunityBio (IBRX) Could Be 45% Undervalued On UAE ANKTIVA Approval

ImmunityBio (IBRX) has received marketing authorization for ANKTIVA in the UAE for two cancer indications, expanding its global footprint. Despite a recent share price pullback, the company is considered 45% undervalued, with a fair value of $13 compared to its last close of $7.17. …

Price to earnings forward of Immunome, Inc. – NASDAQ:IMNM

This article provides a brief overview of Immunome, Inc. (NASDAQ: IMNM) financials, specifically focusing on its forward price-to-earnings ratio. The content appears to be a stub or a section of a larger financial data page on TradingView, indicating that the detailed financial figures for …

Immutep (IMMP) Q2 2026 Earnings: Wider-than-Expected Loss Overshadowed by Steady Clinical Progress - Earnings Decline Risk

Immunic Inc. (IMUX) Holds Near $14 as Shares Consolidate Between Key Support and Resistance - Market Leader Picks

Immuron Limited (IMRN) Slips 1.8% as ADR Tests Key $1.04 Support - Mutual Fund Flow

Scinai Immunotherapeutics Ltd (SCNI) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Scinai Immunotherapeutics Ltd (SCNI), noting its current valuation score of 7.40, ranking 176 out of 385 in its industry. It highlights the company's P/E ratio of -0.08, which is significantly below its recent high and above its …

Immunovant (IMVT.US) will release its earnings report before the market opens on August 6.

Immunovant (IMVT.US) is scheduled to release its earnings report before the market opens on August 6. This announcement provides key information for investors and stakeholders anticipating the company's financial performance.

Immunome Inc (IMNM) Financial Health: Profitability & Balance Sheet Analysis

The article analyzes the financial health of Immunome Inc (IMNM), noting its robust financial status with a score of 7.15 out of 10, ranking 137th in the Biotechnology & Medical Research industry. Despite this, the company exhibits low operating efficiency, with recent quarterly revenue …

Immunovant (Nasdaq:IMVT) - Stock Analysis

This Simply Wall St analysis of Immunovant (IMVT) provides an overview of the company's financial health, future growth prospects, past performance, and insider transactions. It highlights the company's focus on developing targeted therapies for autoimmune diseases, particularly IMVT-1402, and discusses recent news, analyst ratings, …

Immunome Stock Price Forecast. Should You Buy IMNM?

AC Immune SA Revenue Breakdown – HAM:IMR

AC Immune SA generated €3.84 million in revenue last year, primarily from its Therapeutic and Diagnostic Products segment, which contributed €3.66 million. This is a significant decrease from the previous year's €29.95 million. The majority of this revenue, €3.66 million, originated from Switzerland.

Number of shareholders of Estrella Immunopharma, Inc. – NASDAQ:ESLAW

This article from TradingView is a placeholder or an incomplete data point regarding the number of shareholders for Estrella Immunopharma, Inc. (NASDAQ: ESLAW). It currently shows no specific shareholder data, indicating that the information is either unavailable or has not yet been populated for …